DOVONEX Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Dovonex, and when can generic versions of Dovonex launch?
Dovonex is a drug marketed by Leo Pharma As and Leo Pharm and is included in three NDAs.
The generic ingredient in DOVONEX is calcipotriene. There are twelve drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the calcipotriene profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Dovonex
A generic version of DOVONEX was approved as calcipotriene by FOUGERA PHARMS on May 6th, 2008.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for DOVONEX?
- What are the global sales for DOVONEX?
- What is Average Wholesale Price for DOVONEX?
Summary for DOVONEX
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 3 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 51 |
| Clinical Trials: | 13 |
| Patent Applications: | 5,629 |
| Drug Prices: | Drug price information for DOVONEX |
| What excipients (inactive ingredients) are in DOVONEX? | DOVONEX excipients list |
| DailyMed Link: | DOVONEX at DailyMed |
Recent Clinical Trials for DOVONEX
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National Cancer Institute (NCI) | Phase 2 |
| Wake Forest University Health Sciences | Early Phase 1 |
| Guangdong Provincial Hospital of Traditional Chinese Medicine | N/A |
Paragraph IV (Patent) Challenges for DOVONEX
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| DOVONEX | Topical Cream | calcipotriene | 0.005% | 020554 | 1 | 2009-12-02 |
| DOVONEX | Topical Solution | calcipotriene | 0.005% | 020611 | 1 | 2006-05-19 |
US Patents and Regulatory Information for DOVONEX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Leo Pharma As | DOVONEX | calcipotriene | CREAM;TOPICAL | 020554-001 | Jul 22, 1996 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Leo Pharma As | DOVONEX | calcipotriene | OINTMENT;TOPICAL | 020273-001 | Dec 29, 1993 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Leo Pharm | DOVONEX | calcipotriene | SOLUTION;TOPICAL | 020611-001 | Mar 3, 1997 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for DOVONEX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Leo Pharma As | DOVONEX | calcipotriene | CREAM;TOPICAL | 020554-001 | Jul 22, 1996 | ⤷ Sign Up | ⤷ Sign Up |
| Leo Pharma As | DOVONEX | calcipotriene | OINTMENT;TOPICAL | 020273-001 | Dec 29, 1993 | ⤷ Sign Up | ⤷ Sign Up |
| Leo Pharm | DOVONEX | calcipotriene | SOLUTION;TOPICAL | 020611-001 | Mar 3, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| Leo Pharm | DOVONEX | calcipotriene | SOLUTION;TOPICAL | 020611-001 | Mar 3, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| Leo Pharm | DOVONEX | calcipotriene | SOLUTION;TOPICAL | 020611-001 | Mar 3, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| Leo Pharma As | DOVONEX | calcipotriene | CREAM;TOPICAL | 020554-001 | Jul 22, 1996 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for DOVONEX
See the table below for patents covering DOVONEX around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Spain | 2000823 | METODO PARA LA PRODUCCION DE COMPUESTOS ANALOGOS A LA VITAMINA D (NOVEL VITAMIN D ANALOGUES.) | ⤷ Sign Up |
| New Zealand | 259679 | CALCIPOTRIOL (CALCIPOTRIENE) MONOHYDRATE (24-CYCLOPROPYL-9-10- SECOCHOLA-5,7,10(19),22-TETRAENE-1,3,24-TRIOL) AND PHARMACEUTICAL COMPOSITIONS | ⤷ Sign Up |
| Japan | H08505612 | ⤷ Sign Up | |
| Russian Federation | 2128646 | CALCIPOTRIOL HYDRATE, PHARMACEUTICAL COMPOSITION | ⤷ Sign Up |
| European Patent Office | 0227826 | NOVEL VITAMIN D ANALOGUES | ⤷ Sign Up |
| Australia | 6196186 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
